Liquidia (LQDA) Settlement Clears The Air But Is The Stock Fully Valued
Liquidia (LQDA) recently settled its long running YUTREPIA dispute with United Therapeutics, agreeing to structured payments through 2027 that clear a key legal hurdle around its pulmonary arterial hypertension franchise.
Liquidia’s share price has swung sharply over 2026, with a 7.46% 1 day share price return and 24.16% 7 day return after the settlement, set against a 30 day share price decline of 36.81% and 90 day drop of 50.53%. Total shareholder returns of 90.57% over one year and more than 10x over five years show long term holders have still seen very large gains.
Scan how other rare disease and healthcare developers are priced after Liquidia’s legal reset by reviewing the hand picked 34 healthcare AI stocks alongside this settlement story.
Liquidia now splits investors. One side sees a rare disease leader cleaned up by the YUTREPIA settlement. The other side sees legal clarity already priced in. Which case does the current valuation reflect?
Most Popular Narrative: 20.3% Undervalued
On the Simply Wall St fair value narrative, Liquidia screens at a $53.50 estimate versus the recent $42.65 close. This comparison puts the legal reset and pipeline outlook in sharper context for where sentiment sits today.
Planned expansion of North Carolina manufacturing capacity, with a new facility targeted to potentially triple production capability by 2026, positions Liquidia to meet higher volume needs for YUTREPIA and future products such as L606. This can support scaling benefits across cost of goods, operating margins and long term earnings power if demand materializes.
See why 6 investors see Liquidia as 20% undervalued.
Result: Fair Value of $53.50 (UNDERVALUED)
Still, the fair value story can unravel if the narrower YUTREPIA label limits uptake more than expected, or if L606 legal and trial outcomes disappoint.
Find out about the key risks to this Liquidia narrative.
Another View: What Liquidia’s P/E Is Telling You
Liquidia might look cheap on fair value models, yet its 27.5x P/E is richer than the US Pharmaceuticals industry on 15.6x and slightly above its own fair ratio of 26x. Peers on 34.5x trade even higher. Is the premium a cushion or a source of downside risk if growth expectations reset?
For a closer look at what the current pricing gap could mean for future returns, sense check these numbers against the valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown..
Next Steps
Mixed signals often create the real opportunity set. If you want to move before consensus hardens, review the underlying data and weigh Liquidia’s story against the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Liquidia?
If Liquidia has sharpened your appetite for opportunity, do not stop here. The next potential winner in your portfolio might be sitting in plain sight.
- Target resilient balance sheets and healthier fundamentals by scanning the list of solid balance sheet and fundamentals (25 results) for businesses built to handle tougher conditions.
- Hunt for potential mispricings by reviewing the 27 high quality undervalued stocks and see which companies the market may be overlooking right now.
- Explore ways to build a steadier income stream by spotting payout heavyweights through the 5 dividend fortresses before competition starts focusing on the same yields.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com